nach oben

Erschienen in:

16.07.2019 | Review Article

Gene expression in stress urinary incontinence: a systematic review

verfasst von: Ilaha Isali, Amr Mahran, Ahmad O. Khalifa, David Sheyn, Mandy Neudecker, Arshna Qureshi, Britt Conroy, Fredrick R. Schumacher, Adonis K. Hijaz, Sherif A. El-Nashar

Erschienen in: International Urogynecology Journal | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

A contribution of genetic factors to the development of stress urinary incontinence (SUI) is broadly acknowledged. This study aimed to: (1) provide insight into the genetic pathogenesis of SUI by gathering and synthesizing the available data from studies evaluating differential gene expression in SUI patients and (2) identify possible novel therapeutic targets and leads.

Methods

A systematic literature search was conducted through September 2017 for the concepts of genetics and SUI. Gene networking connections and gene-set functional analyses of the identified genes as differentially expressed in SUI were performed using GeneMANIA software.

Results

Of 3019 studies, 4 were included in the final analysis. A total of 13 genes were identified as being differentially expressed in SUI patients. Eleven genes were overexpressed: skin-derived antileukoproteinase (SKALP/elafin), collagen type XVII alpha 1 chain (COL17A1), plakophilin 1 (PKP1), keratin 16 (KRT16), decorin (DCN), biglycan (BGN), protein bicaudal D homolog 2 (BICD2), growth factor receptor-bound protein 2 (GRB2), signal transducer and activator of transcription 3 (STAT3), apolipoprotein E (APOE), and Golgi SNAP receptor complex member 1 (GOSR1), while two genes were underexpressed: fibromodulin (FMOD) and glucocerebrosidase (GBA). GeneMANIA revealed that these genes are involved in intermediate filament cytoskeleton and extracellular matrix organization.

Conclusion

Many genes are involved in the pathogenesis of SUI. Furthermore, whole-genome studies are warranted to identify these genetic connections. This study lays the groundwork for future research and the development of novel therapies and SUI biomarkers in clinical practice.

Nur mit Berechtigung zugänglich

Sangsawang B, Sangsawang N. Stress urinary incontinence in pregnant women: a review of prevalence, pathophysiology, and treatment. Int Urogynecol J. 2013;24(6):901–12. https://doi.org/10.1007/s00192-013-2061-7.CrossRefPubMedPubMedCentral

Kwon CS, Lee JH. Prevalence, risk factors, quality of life, and health-care seeking behaviors of female urinary incontinence: results from the 4th Korean National Health and nutrition examination survey VI (2007-2009). Int Neurourol J. 2014;18(1):31–6. https://doi.org/10.5213/inj.2014.18.1.31.CrossRefPubMedPubMedCentral

Khalifa AO, Kavran M, Mahran A, Isali I, Woda J, Flask CA, et al. Stromal derived factor-1 plasmid as a novel injection for treatment of stress urinary incontinence in a rat model. Int Urogynecol J. 2019. https://doi.org/10.1007/s00192-019-03867-3.

Gigliobianco G, Regueros SR. Biomaterials for pelvic floor reconstructive surgery: how can we do better?. 2015; 2015:968087. doi:https://doi.org/10.1155/2015/968087.CrossRef

Ninomiya S, Naito K, Nakanishi K, Okayama H. Prevalence and risk factors of urinary incontinence and overactive bladder in Japanese women. Lower Urinary Tract Symp. 2017. https://doi.org/10.1111/luts.12185.PubMed

Rikard-Bell J, Iyer J, Rane A. Perineal outcome and the risk of pelvic floor dysfunction: a cohort study of primiparous women. Aust N Z J Obstet Gynaecol. 2014;54(4):371–6. https://doi.org/10.1111/ajo.12222.CrossRefPubMed

Hannestad YS, Lie RT, Rortveit G, Hunskaar S. Familial risk of urinary incontinence in women: population based cross sectional study. BMJ (Clinical Res ed). 2004;329(7471):889–91. https://doi.org/10.1136/bmj.329.7471.889.CrossRef

Skoner MM, Thompson WD, Caron VA. Factors associated with risk of stress urinary incontinence in women. Nurs Res. 1994;43(5):301–6.CrossRefPubMed

McKenzie P, Rohozinski J, Badlani G. Genetic influences on stress urinary incontinence. Curr Opin Urol. 2010;20(4):291–5. https://doi.org/10.1097/MOU.0b013e32833a4436.CrossRefPubMed

10.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097.CrossRefPubMedPubMedCentral

11.

Jeong SJ, Kim HJ, Lee BK, Rha W, Oh JJ, Jeong CW, et al. Women with pure stress urinary incontinence symptoms assessed by the initial standard evaluation including measurement of post-void residual volume and a stress test: are urodynamic studies still needed? Neurourol Urodyn. 2012;31(4):508–12. https://doi.org/10.1002/nau.21215.CrossRefPubMed

12.

Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. Newcastle-Ottawa quality assessment Scale, Cohort Studies, 2014.

13.

NHLBI. Quality assessment tool for observational cohort and cross-sectional studies, 2018. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.

14.

Chen B, Wen Y, Zhang Z, Guo Y, Warrington JA, Polan ML. Microarray analysis of differentially expressed genes in vaginal tissues from women with stress urinary incontinence compared with asymptomatic women. Human Reprod (Oxford, England). 2006;21(1):22–9. https://doi.org/10.1093/humrep/dei276.CrossRef

15.

Wen Y, Zhao YY, Li S, Polan ML, Chen BH. Differences in mRNA and protein expression of small proteoglycans in vaginal wall tissue from women with and without stress urinary incontinence. Human Reprod (Oxford, England). 2007;22(6):1718–24. https://doi.org/10.1093/humrep/dem039.CrossRef

16.

Liu X, Lang J, Wu S, Cheng L, Wang W, Zhu L. Differential expression of microRNAs in periurethral vaginal wall tissues of postmenopausal women with and without stress urinary incontinence. Menopause (New York, NY). 2014;21(10):1122–8. https://doi.org/10.1097/gme.0000000000000222.CrossRef

17.

Tong J, Lang J, Zhu L. Microarray analysis of differentially expressed genes in vaginal tissues in postmenopausal women. The role of stress urinary incontinence. Int Urogynecol J. 2010;21(12):1545–51. https://doi.org/10.1007/s00192-010-1222-1.CrossRefPubMed

18.

Kuijpers AL, Pfundt R, Zeeuwen PL, Molhuizen HO, Mariman EC, van de Kerkhof PC, et al. SKALP/elafin gene polymorphisms are not associated with pustular forms of psoriasis. Clin Genet. 1998;54(1):96–101.CrossRefPubMed

19.

Vandermeeren M, Daneels G, Bergers M, van Vlijmen-Willems I, Pol A, Geysen J, et al. Development and application of monoclonal antibodies against SKALP/elafin and other trappin family members. Arch Dermatol Res. 2001;293(7):343–9.CrossRefPubMed

20.

van Bergen BH, Andriessen MP, Spruijt KI, van de Kerkhof PC, Schalkwijk J. Expression of SKALP/elafin during wound healing in human skin. Arch Dermatol Res. 1996;288(8):458–62.CrossRefPubMed

21.

Wiedow O, Schroder JM, Gregory H, Young JA, Christophers E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem. 1990;265(25):14791–5.PubMed

22.

Powell AM, Sakuma-Oyama Y, Oyama N, Black MM. Collagen XVII/BP180: a collagenous transmembrane protein and component of the dermoepidermal anchoring complex. Clin Exp Dermatol. 2005;30(6):682–7. https://doi.org/10.1111/j.1365-2230.2005.01937.x.CrossRefPubMed

23.

Hopkinson SB, Findlay K, deHart GW, Jones JC. Interaction of BP180 (type XVII collagen) and alpha6 integrin is necessary for stabilization of hemidesmosome structure. J Investig Dermatol. 1998;111(6):1015–22. https://doi.org/10.1046/j.1523-1747.1998.00452.x.CrossRefPubMed

24.

Varki R, Sadowski S, Pfendner E, Uitto J. Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants. J Med Genet. 2006;43(8):641–52. https://doi.org/10.1136/jmg.2005.039685.CrossRefPubMedPubMedCentral

25.

Sobolik-Delmaire T, Reddy R, Pashaj A, Roberts BJ, Wahl JK 3rd. Plakophilin-1 localizes to the nucleus and interacts with single-stranded DNA. J Investig Dermatol. 2010;130(11):2638–46. https://doi.org/10.1038/jid.2010.191.CrossRefPubMed

26.

Sprecher E, Molho-Pessach V, Ingber A, Sagi E, Indelman M, Bergman R. Homozygous splice site mutations in PKP1 result in loss of epidermal plakophilin 1 expression and underlie ectodermal dysplasia/skin fragility syndrome in two consanguineous families. J Investig Dermatol. 2004;122(3):647–51. https://doi.org/10.1111/j.0022-202X.2004.22335.x.CrossRefPubMed

27.

Yang C, Fischer-Keso R, Schlechter T, Strobel P, Marx A, Hofmann I. Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression. Tumour Biol : J Int Soc Oncodev Biol Med. 2015;36(12):9567–77. https://doi.org/10.1007/s13277-015-3628-3.CrossRef

28.

Lessard JC, Pina-Paz S, Rotty JD, Hickerson RP, Kaspar RL, Balmain A, et al. Keratin 16 regulates innate immunity in response to epidermal barrier breach. Proc Natl Acad Sci U S A. 2013;110(48):19537–42. https://doi.org/10.1073/pnas.1309576110.CrossRefPubMedPubMedCentral

29.

Duverger O, Cross MA, Smith FJD, Morasso MI. Enamel anomalies in a pachyonychia congenita patient with a mutation in KRT16. J Investig Dermatol. 2018. https://doi.org/10.1016/j.jid.2018.07.005.CrossRefPubMed

30.

Tajerian M, Hung V, Khan H, Lahey LJ, Sun Y, Birklein F, et al. Identification of KRT16 as a target of an autoantibody response in complex regional pain syndrome. Exp Neurol. 2017;287(Pt 1):14–20. https://doi.org/10.1016/j.expneurol.2016.10.011.CrossRefPubMed

31.

Kalamajski S, Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol : J Int Soc Matrix Biol. 2010;29(4):248–53. https://doi.org/10.1016/j.matbio.2010.01.001.CrossRef

32.

Jarvinen TA, Prince S. Decorin: a growth factor antagonist for tumor growth inhibition. Biomed Res Int. 2015;2015:654765. https://doi.org/10.1155/2015/654765.CrossRefPubMedPubMedCentral

33.

Svensson L, Heinegard D, Oldberg A. Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4-5. J Biol Chem. 1995;270(35):20712–6.CrossRefPubMed

34.

Traupe H, van den Ouweland AM, van Oost BA, Vogel W, Vetter U, Warren ST, et al. Fine mapping of the human biglycan (BGN) gene within the Xq28 region employing a hybrid cell panel. Genomics. 1992;13(2):481–3.CrossRefPubMed

35.

Liu B, Xu T, Xu X, Cui Y, Xing X. Biglycan promotes the chemotherapy resistance of colon cancer by activating NF-kappaB signal transduction. Mol Cell Biochem. 2018. https://doi.org/10.1007/s11010-018-3365-1.CrossRefPubMed

36.

Hu L, Zang MD, Wang HX, Li JF, Su LP, Yan M, et al. Biglycan stimulates VEGF expression in endothelial cells by activating the TLR signaling pathway. Mol Oncol. 2016;10(9):1473–84. https://doi.org/10.1016/j.molonc.2016.08.002.CrossRefPubMedPubMedCentral

37.

Martinez Carrera LA, Gabriel E, Donohoe CD, Holker I, Mariappan A, Storbeck M, et al. Novel insights into SMALED2: BICD2 mutations increase microtubule stability and cause defects in axonal and NMJ development. Hum Mol Genet. 2018;27(10):1772–84. https://doi.org/10.1093/hmg/ddy086.CrossRefPubMed

38.

Huang X, Fan D. A novel mutation of BICD2 gene associated with juvenile amyotrophic lateral sclerosis. Amyotrophic Later Sclerosis Frontotemp Degen. 2017;18(5-6):454–6. https://doi.org/10.1080/21678421.2017.1304557.CrossRef

39.

Yoshioka M, Morisada N, Toyoshima D, Yoshimura H, Nishio H, Iijima K, et al. Novel BICD2 mutation in a Japanese family with autosomal dominant lower extremity-predominant spinal muscular atrophy-2. Brain Dev. 2018;40(4):343–7. https://doi.org/10.1016/j.braindev.2017.12.001.CrossRefPubMed

40.

Roy K, Raychaudhuri M, Chakrabarti O, Mukhopadhyay D. Growth factor receptor-bound protein 2 promotes autophagic removal of amyloid-beta protein precursor intracellular domain overload in neuronal cells. J Alzheimer’s Dis : JAD. 2014;38(4):881–95. https://doi.org/10.3233/jad-130929.CrossRef

41.

Majumder P, Roy K, Singh BK, Jana NR, Mukhopadhyay D. Cellular levels of Grb2 and cytoskeleton stability are correlated in a neurodegenerative scenario, 2017. 10 (5):655-669. doi:https://doi.org/10.1242/dmm.027748.CrossRef

42.

You L, Wang Z, Li H, Shou J, Jing Z, Xie J, et al. The role of STAT3 in autophagy. Autophagy. 2015;11(5):729–39. https://doi.org/10.1080/15548627.2015.1017192.CrossRefPubMedPubMedCentral

43.

Chen X, Chen C, Hao J, Zhang J, Zhang F. Effect of CLIP3 upregulation on astrocyte proliferation and subsequent glial scar formation in the rat spinal cord via STAT3 pathway after injury, 2018. 64 (1):117-128. doi:https://doi.org/10.1007/s12031-017-0998-6.CrossRefPubMed

44.

Herrmann JE, Imura T, Song B, Qi J, Ao Y, Nguyen TK, et al. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci. 2008;28(28):7231–43. https://doi.org/10.1523/jneurosci.1709-08.2008.CrossRefPubMedPubMedCentral

45.

Yang X, Chen S, Shao Z, Li Y, Wu H, Li X, et al. Apolipoprotein E deficiency exacerbates spinal cord injury in mice: inflammatory response and oxidative stress mediated by NF-kappaB signaling pathway. Front Cell Neurosci. 2018;12:142. https://doi.org/10.3389/fncel.2018.00142.CrossRefPubMedPubMedCentral

46.

Cheng X, Zheng Y, Bu P, Qi X, Fan C, Li F, et al. Apolipoprotein E as a novel therapeutic neuroprotection target after traumatic spinal cord injury. Exp Neurol. 2018;299(Pt A):97–108. https://doi.org/10.1016/j.expneurol.2017.10.014.CrossRefPubMed

47.

Cheng B, Zhang Y, Guo G, Gao Y. Crystallization and preliminary X-ray diffraction analysis of Gos1p, a yeast SNARE protein. Acta Crystallographica Sect F, Struct Biol Commun. 2014;70(Pt 7):967–9. https://doi.org/10.1107/s2053230x14011704.CrossRef

48.

Nichols BJ, Pelham HR. SNAREs and membrane fusion in the Golgi apparatus. Biochim Biophys Acta. 1998;1404(1-2):9–31.CrossRefPubMed

49.

Mikaelsson E, Danesh-Manesh AH, Luppert A, Jeddi-Tehrani M, Rezvany MR, Sharifian RA, et al. Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood. 2005;105(12):4828–35. https://doi.org/10.1182/blood-2004-10-3941.CrossRefPubMed

50.

Zheng Z, James AW, Li C, Jiang W, Wang JZ, Chang GX, Lee KS, Chen F, Berthiaume EA, Chen Y, Pan HC, Chen EC, Li W, Zhao Z, Zhang X, Ting K, Soo C. Fibromodulin reduces scar formation in adult cutaneous wounds by eliciting a fetal-like phenotype. Signal transduction and targeted therapy. 2017; 2. doi:https://doi.org/10.1038/sigtrans.2017.50.

51.

Barth BM, Shanmugavelandy SS, Tacelosky DM, Kester M, Morad SA, Cabot MC. Gaucher’s disease and cancer: a sphingolipid perspective. Crit Rev Oncog. 2013;18(3):221–34.CrossRefPubMedPubMedCentral

52.

Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29(5):567–83. https://doi.org/10.1002/humu.20676.CrossRefPubMed

53.

Hildebrand A, Romaris M, Rasmussen L, Heinegård D, Twardzik D, Border W, et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. Biochem J. 1994;302(2):527–34.CrossRefPubMedPubMedCentral

54.

Campeau L, Gorbachinsky I, Badlani GH, Andersson KE. Pelvic floor disorders: linking genetic risk factors to biochemical changes. BJU Int. 2011;108(8):1240–7. https://doi.org/10.1111/j.1464-410X.2011.10385.x.CrossRefPubMed

55.

Lyons MR, West AE. Mechanisms of specificity in neuronal activity-regulated gene transcription. Prog Neurobiol. 2011;94(3):259–95. https://doi.org/10.1016/j.pneurobio.2011.05.003.CrossRefPubMedPubMedCentral

Titel: Gene expression in stress urinary incontinence: a systematic review
verfasst von: Ilaha Isali
Amr Mahran
Ahmad O. Khalifa
David Sheyn
Mandy Neudecker
Arshna Qureshi
Britt Conroy
Fredrick R. Schumacher
Adonis K. Hijaz
Sherif A. El-Nashar
Publikationsdatum: 16.07.2019
Verlag: Springer International Publishing
Erschienen in: International Urogynecology Journal / Ausgabe 1/2020
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-019-04025-5

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Diagnostic value of pelvic floor ultrasonography for diagnosis of pelvic organ prolapse: a systematic review

Does estrogen deprivation affect pelvic floor muscle contractility?

Polymorphism rs1800255 from COL3A1 gene and the risk for pelvic organ prolapse

Genetic association in female stress urinary incontinence based on proteomic findings: a case-control study